112 related articles for article (PubMed ID: 23327722)
21. The role of thrombin-activatable fibrinolysis inhibitor in diabetic wound healing.
Verkleij CJ; Roelofs JJ; Havik SR; Meijers JC; Marx PF
Thromb Res; 2010 Nov; 126(5):442-6. PubMed ID: 20828799
[TBL] [Abstract][Full Text] [Related]
22. Thrombin, thrombomodulin and TAFI in the molecular link between coagulation and fibrinolysis.
Nesheim M; Wang W; Boffa M; Nagashima M; Morser J; Bajzar L
Thromb Haemost; 1997 Jul; 78(1):386-91. PubMed ID: 9198184
[TBL] [Abstract][Full Text] [Related]
23. Postprandial thrombin activatable fibrinolysis inhibitor and markers of endothelial dysfunction in type 2 diabetic patients.
Rigla M; Wägner AM; Borrell M; Mateo J; Foncuberta J; de Leiva A; Ordóñez-Llanos J; Pérez A
Metabolism; 2006 Nov; 55(11):1437-42. PubMed ID: 17046544
[TBL] [Abstract][Full Text] [Related]
24. Low levels of thrombin activatable fibrinolysis inhibitor (TAFI) in patients with chronic liver disease.
Van Thiel DH; George M; Fareed J
Thromb Haemost; 2001 Apr; 85(4):667-70. PubMed ID: 11341503
[TBL] [Abstract][Full Text] [Related]
25. Thrombin-activatable fibrinolysis inhibitor activity and global fibrinolytic capacity in Type 1 diabetes: evidence for normal fibrinolytic state.
Harmanci A; Kandemir N; Dagdelen S; Gonc N; Buyukasik Y; Alikasifoglu A; Kirazli S; Ozon A; Gurlek A
J Diabetes Complications; 2006; 20(1):40-4. PubMed ID: 16389166
[TBL] [Abstract][Full Text] [Related]
26. The effects of hyperglycaemia on thrombin-activatable fibrinolysis inhibitor.
Verkleij CJ; Nieuwdorp M; Gerdes VE; Mörgelin M; Meijers JC; Marx PF
Thromb Haemost; 2009 Sep; 102(3):460-8. PubMed ID: 19718465
[TBL] [Abstract][Full Text] [Related]
27. Thrombin-mediated activation of factor XI results in a thrombin-activatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis.
Von dem Borne PA; Bajzar L; Meijers JC; Nesheim ME; Bouma BN
J Clin Invest; 1997 May; 99(10):2323-7. PubMed ID: 9153272
[TBL] [Abstract][Full Text] [Related]
28. The defective down regulation of fibrinolysis in haemophilia A can be restored by increasing the TAFI plasma concentration.
Mosnier LO; Lisman T; van den Berg HM; Nieuwenhuis HK; Meijers JC; Bouma BN
Thromb Haemost; 2001 Oct; 86(4):1035-9. PubMed ID: 11686321
[TBL] [Abstract][Full Text] [Related]
29. Thrombin activatable fibrinolysis inhibitor in hypertensive kidney transplant recipients.
Malyszko J; Malyszko JS; Hryszko T; Mysliwiec M
Transplant Proc; 2006; 38(1):105-7. PubMed ID: 16504676
[TBL] [Abstract][Full Text] [Related]
30. Thrombin activatable fibrinolysis inhibitor and other hemostatic parameters in patients with polycystic ovary syndrome.
Oral B; Mermi B; Dilek M; Alanoğlu G; Sütçü R
Gynecol Endocrinol; 2009 Feb; 25(2):110-6. PubMed ID: 19253106
[TBL] [Abstract][Full Text] [Related]
31. [Changes in hemostasis and fibrinolysis in gestational diabetes].
Kvasnicka J; Bendl J; Zivný J; Umlaufová A; Maslowská H
Cas Lek Cesk; 1996 Feb; 135(4):106-10. PubMed ID: 8625379
[TBL] [Abstract][Full Text] [Related]
32. Clot lysis time and thrombin activatable fibrinolysis inhibitor in severe preeclampsia with or without associated antiphospholipid antibodies.
Martínez-Zamora MA; Tassies D; Carmona F; Espinosa G; Cervera R; Reverter JC; Balasch J
J Reprod Immunol; 2010 Nov; 86(2):133-40. PubMed ID: 20594598
[TBL] [Abstract][Full Text] [Related]
33. Thrombin activatable fibrinolysis inhibitor (TAFI)--how does thrombin regulate fibrinolysis?
Bouma BN; Mosnier LO
Ann Med; 2006; 38(6):378-88. PubMed ID: 17008302
[TBL] [Abstract][Full Text] [Related]
34. Fibrinolytic inhibitor levels and polymorphisms in Behçet disease and their association with thrombosis.
Ricart JM; Ramón LA; Vayá A; España F; Santaolaria ML; Todolí J; Castelló R; Fontcuberta J; Estellés A
Br J Haematol; 2008 May; 141(5):716-9. PubMed ID: 18341631
[TBL] [Abstract][Full Text] [Related]
35. Fibrinolytic dysfunction in insulin-resistant women with previous gestational diabetes.
Farhan S; Winzer C; Tura A; Quehenberger P; Bieglmaier C; Wagner OF; Huber K; Waldhäusl W; Pacini G; Kautzky-Willer A
Eur J Clin Invest; 2006 May; 36(5):345-52. PubMed ID: 16634839
[TBL] [Abstract][Full Text] [Related]
36. Thrombin activatable fibrinolysis inhibitor (TAFI) levels in hypertensive patients and a comparison of the effects of amlodipine and ramipril on TAFI levels.
Ozkan G; Ulusoy S; Sönmez M; Karahan SC; Menteşe A; Kaynar K; Bektaş O
Clin Exp Hypertens; 2013; 35(2):134-40. PubMed ID: 22799880
[TBL] [Abstract][Full Text] [Related]
37. Association of functional thrombin-activatable fibrinolysis inhibitor (TAFI) with conventional cardiovascular risk factors and its correlation with other hemostatic factors in a Spanish population.
Santamaría A; Borrell M; Oliver A; Ortín R; Forner R; Coll I; Mateo J; Souto JC; Fontcuberta J
Am J Hematol; 2004 Aug; 76(4):348-52. PubMed ID: 15282667
[TBL] [Abstract][Full Text] [Related]
38. Assessment of thrombin-activatable fibrinolysis inhibitor (TAFI) plasma levels in inflammatory bowel diseases.
Saibeni S; Bottasso B; Spina L; Bajetta M; Danese S; Gasbarrini A; de Franchis R; Vecchi M
Am J Gastroenterol; 2004 Oct; 99(10):1966-70. PubMed ID: 15447757
[TBL] [Abstract][Full Text] [Related]
39. Thrombin activatable fibrinolysis inhibitor (TAFI): relationship to hemostatic alteration in patients with beta-thalassemia.
Mokhtar GM; Matter RM; Shawki H; Abdel Aziz MM
Pediatr Hematol Oncol; 2010 Aug; 27(5):363-73. PubMed ID: 20670166
[TBL] [Abstract][Full Text] [Related]
40. Thrombin activatable fibrinolysis inhibitor (TAFI) in human amniotic fluid. A preliminary study.
Uszyński W; Uszyński M; Zekanowska E
Thromb Res; 2007; 119(2):241-5. PubMed ID: 16540154
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
